The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called benfotiamine as a possible treatment for Alzheimer’s disease (AD). Benfotiamine is a lab-made version of vitamin B1 (thiamine). The study aims to determine whether the drug slows down the progression of the symptoms of early Alzheimer’s disease. Participants will be randomly assigned to receive either the study drug or placebo (inactive substance).